LYEL compared with SPTX: revenue, margins and what each company keeps, and the suppliers and customers both name

LYELLyell Immunopharma, Inc.

Mkt capRevenueRevenue

SPTXSeaport Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

LYELLyell Immunopharma, Inc.

SPTXSeaport Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LYEL2 of 4 reports

0 of 2at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±28.5%▼−2.79%×0.10

Q2 FY26±35.4%▲+3.52%×0.10

SPTX2 of 4 reports

Reportimpliedrealized× implied

Q3 FY26—▲+2.09%—

Q2 FY26—▲+0.93%—

= impliedLYEL realized, solidSPTX realized, hatchedOne scale, both sides: full bar = 36%× = |realized| ÷ impliedSource: market data

LYELLyell Immunopharma, Inc.

14.85▼−1.03%· post 14.85

Mkt cap$365.3MRevenue$3,000Q3 FY26Revenue$36,000FY25

SPTXSeaport Therapeutics, Inc.

21.51▲+5.51%· post 21.48

ClosedNov 6 '26

Mkt cap$1.2BRevenue—Revenue—

Compare

ClosedNov 6 '26

LYELLyell Immunopharma, Inc.

SPTXSeaport Therapeutics, Inc.

14.85▼−1.03%post 14.85

Price

21.51▲+5.51%post 21.48

$365.3M

Mkt cap

$1.2B

Q3 FY26$3,000

Revenue

—

FY25$36,000

Revenue

—

LYEL14.85▼−1.03%vsSPTX21.51▲+5.51%ClosedNov 6 '26